AZN
LLY
NVO
PFE
A very 2026 health-policy twofer
President Trump just did two things at once: told the FDA to move faster on psychedelic drug reviews, and rolled out TrumpRx, a coupon-style website meant to steer patients toward lower prices. It’s part mental-health moonshot, part “please stop paying sticker shock at the pharmacy.”
Psychedelics, but make it official
The headline grabber is ibogaine. The executive order directs the FDA to accelerate its work on psychedelics tied to treatment research, and Trump said the federal government will put up $50 million for ibogaine studies. That matters because if the clinical evidence keeps improving, regulators could eventually open the door to rescheduling — the bureaucratic equivalent of moving a drug from the kiddie table to the adults’ section.
Veterans’ groups have argued ibogaine may help with PTSD, and FDA Commissioner Marty Makary said agency decisions could come as soon as this summer. Translation: this isn’t just vibes and wellness-culture chatter anymore. There’s now a real federal push behind the science.
Meanwhile, pharma gets the coupon treatment
The TrumpRx launch is separate, but it’s part of the same pressure campaign on drug costs. The site doesn’t sell meds; it points users to lower prices and printable coupons. The White House says 40 medicines tied to “most-favored-nation” pricing deals are already listed, including drugs from AstraZeneca, Eli Lilly, Novo Nordisk, and Pfizer.
That doesn’t automatically change the companies’ fundamentals overnight, but it does keep pricing politics front and center — especially for names selling pricey GLP-1s and other brand-name meds. Big picture: Washington is trying to speed up one new market while turning the screws on another. Fun for patients, less fun for the spreadsheet people.